CN101933961B - Sanicula lamelligera hance sesquiterpene extract for treating influenza - Google Patents
Sanicula lamelligera hance sesquiterpene extract for treating influenza Download PDFInfo
- Publication number
- CN101933961B CN101933961B CN2010102751242A CN201010275124A CN101933961B CN 101933961 B CN101933961 B CN 101933961B CN 2010102751242 A CN2010102751242 A CN 2010102751242A CN 201010275124 A CN201010275124 A CN 201010275124A CN 101933961 B CN101933961 B CN 101933961B
- Authority
- CN
- China
- Prior art keywords
- extract
- sesquiterpene
- herba saniculae
- saniculae lamelligerae
- lamelligerae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229930004725 sesquiterpene Natural products 0.000 title claims abstract description 96
- 150000004354 sesquiterpene derivatives Chemical class 0.000 title claims abstract description 96
- 239000000284 extract Substances 0.000 title claims abstract description 80
- 206010022000 influenza Diseases 0.000 title abstract description 17
- 241001660187 Sanicula lamelligera Species 0.000 title abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 38
- 230000000694 effects Effects 0.000 claims abstract description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 138
- 229960004756 ethanol Drugs 0.000 claims description 59
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 33
- 238000010828 elution Methods 0.000 claims description 22
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 16
- 239000000287 crude extract Substances 0.000 claims description 16
- 239000011347 resin Substances 0.000 claims description 16
- 229920005989 resin Polymers 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000003480 eluent Substances 0.000 claims description 12
- 239000012567 medical material Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 208000037797 influenza A Diseases 0.000 claims description 9
- 239000003463 adsorbent Substances 0.000 claims description 8
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 8
- 239000001569 carbon dioxide Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 6
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 abstract description 16
- 231100000331 toxic Toxicity 0.000 abstract description 7
- 230000002588 toxic effect Effects 0.000 abstract description 7
- 230000035755 proliferation Effects 0.000 abstract description 6
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 3
- 238000007670 refining Methods 0.000 abstract description 2
- 206010035737 Pneumonia viral Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000002110 toxicologic effect Effects 0.000 abstract 1
- 231100000027 toxicology Toxicity 0.000 abstract 1
- 208000009421 viral pneumonia Diseases 0.000 abstract 1
- 210000001161 mammalian embryo Anatomy 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 241000287828 Gallus gallus Species 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 7
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000001291 vacuum drying Methods 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 229940100050 virazole Drugs 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 206010069767 H1N1 influenza Diseases 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 230000000274 adsorptive effect Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 201000010740 swine influenza Diseases 0.000 description 4
- 210000003837 chick embryo Anatomy 0.000 description 3
- 238000003810 ethyl acetate extraction Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 231100000820 toxicity test Toxicity 0.000 description 3
- 238000009602 toxicology test Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 244000089742 Citrus aurantifolia Species 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000736038 Sanicula Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011416 Croup infectious Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100427174 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) mus-8 gene Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 201000010549 croup Diseases 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000004518 granules dosage form Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- 229960002194 oseltamivir phosphate Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
Abstract
The invention discloses a sanicula lamelligera hance sesquiterpene extract, which is characterized in that: the total sesquiterpene content of the extract is over 30 percent. The sanicula lamelligera hance sesquiterpene extract is prepared by extracting and refining traditional Chinese medicine sanicula lamelligera hance. Pharmacodynamic and toxicologic experiments prove that the sanicula lamelligera hance sesquiterpene extract has the effects of obviously inhibiting the proliferation of influenza virus and resisting mouse influenza viral pneumonia, and has small toxic and side effects. The invention also discloses medicinal application of the sanicula lamelligera hance sesquiterpene extract.
Description
Affiliated technical field
The invention belongs to the pharmaceutical preparations technology field, relate to a kind of effective site of from the Chinese medicine Herba Saniculae lamelligerae, extracting, the invention still further relates to the method for preparing and the medical usage thereof of this effective site.
Background technology
Influenza (influenza; Influenza) by due to influenza virus (influenza virus) respiratory tract infection; From 1918 in the U.S. popular and have swept the globe since; The loss that influenza causes the mankind occupies first of the infectious disease, in the influenza that takes place, and the 80%th, influenza A H1N1.Current; Influenza A H1N1 just have swepts the globe as a kind of viral infectious of serious harm public health, is threatening human life; According to China's Ministry of Public Health statistics; By on January 31st, 2010,31 the province accumulative totals in the whole nation reported the influenza A H1N1 confirmed cases 12.6 ten thousand examples, wherein dead 775 examples.
The chemical drugs of existing treatment influenza has, like amantadine, rimantadine, and zanamivir, Oseltamivir (oseltamivir phosphate capsule capsule), ribavirin etc.; Though certain therapeutic effect is arranged; But side effect is big, simultaneously, does not have effect for the variation and the influenza virus of modification.And the antiviral unique curative effect of Chinese medicine has obtained globally generally acknowledging; The treatment by Chinese herbs influenza is " multicomponent, multipath, many target spots " onset; No matter how influenza virus makes a variation all effective with modification, therefore, the medicine of from Chinese medicine, seeking and develop the treatment influenza has broad prospects.
The Chinese medicine Herba Saniculae lamelligerae records in " Sichuan Province's Chinese herbal medicine standard " tentative original text version in 1979; The dry herb that belongs to (Sanicula) plant thin slice sanicle Sanicula lamelligera Hance for the Umbelliferae sanicle; Have the effect that relieving cough and resolving phlegm, promoting the circulation of blood stimulate the menstrual flow, be used for cold cough, women's amenorrhea lumbago.Also be the medicine of commonly using of the Miao ethnic group and the Yao nationality simultaneously, Miao ethnic group practises and claims " hair Herba Apii graveolentis, Fructus Fici Pumilae, milk beans close ", and the Yao nationality practises and claims " SHUIHUANGLIAN, XUEJINGCAO ".
Herba Saniculae lamelligerae treatment flu with a long history, " Tian Bao book on Chinese herbal medicine " (book on Chinese herbal medicine of southwest) of the Qing Dynasty is just on the books: " Herba Saniculae lamelligerae is a Herba Christiae Obcordatae, specially wraps the infantum tetanus croup cough of reducing phlegm again, claims the first, pestilent cold ".Herba Saniculae lamelligerae in Sichuan Province so that the among the people of southwest all using, mainly use cold cough, especially treat influenza, have wide, the resourceful characteristics of distribution, simultaneously, formed the medical material commodity.
Through retrieval, Shang Weijian is about the grippal bibliographical information of Herba Saniculae lamelligerae sesquiterpene extract for treating.
Summary of the invention
The purpose of this invention is to provide a kind of high-efficiency low-toxicity Herba Saniculae lamelligerae sesquiterpene extract.
Another object of the present invention provides above-mentioned Herba Saniculae lamelligerae sesquiterpene preparation method of extract.
A further object of the invention provide above-mentioned Herba Saniculae lamelligerae sesquiterpene extract medical usage.
The technical solution adopted for the present invention to solve the technical problems is:
A kind of Herba Saniculae lamelligerae sesquiterpene extract, it is the sesquiterpene of from the Chinese medicine Herba Saniculae lamelligerae, extracting, wherein total sesquiterpene content is more than 30%;
And this Herba Saniculae lamelligerae sesquiterpene extract is through any one extracts from the Chinese medicine Herba Saniculae lamelligerae and makes in following two kinds of methods:
The method I comprises the steps:
(1) preparation Herba Saniculae lamelligerae crude extract: get the Herba Saniculae lamelligerae medical material, add 60%～95% ethanol and extract, filter, extracting solution, this extracting solution is concentrated, promptly get the Herba Saniculae lamelligerae crude extract.
(2) the Herba Saniculae lamelligerae crude extract that (1) step is made adds an amount of anhydrous alcohol solution, mixes thoroughly with the macroporous adsorbent resin with weight, adds the water of dehydrated alcohol amount more than 10 times; Stir, be added on handled on the low polar macroporous adsorbent resin column, earlier with 30% low-concentration ethanol eluting; With this low-concentration ethanol eluent discard need not, the ethanol elution of reuse 40%～95% is collected eluent; Reclaim ethanol, drying promptly gets Herba Saniculae lamelligerae sesquiterpene extract.
The method II comprises the steps:
(1) preparation Herba Saniculae lamelligerae crude extract: get the Herba Saniculae lamelligerae medical material, be ground into fine powder, put into the carbon dioxide supercritical fluid extraction jar, under certain condition, extracted 2～10 hours, from knockout drum tell the Herba Saniculae lamelligerae crude extract.
(2) the Herba Saniculae lamelligerae crude extract that makes of (1) step is added an amount of anhydrous alcohol solution, be added on the MCI Gel resin column of using water treatment, earlier with 10%～40% ethanol elution; This low-concentration ethanol eluent is discarded need not; The ethanol elution of reuse 50%～95% is collected eluent, reclaims ethanol; Drying promptly gets Herba Saniculae lamelligerae sesquiterpene extract.
If necessary, refining Herba Saniculae lamelligerae sesquiterpene extract, available ethyl acetate is further purified processing, to make the high Herba Saniculae lamelligerae sesquiterpene extract of total sesquiterpene content.
In the Herba Saniculae lamelligerae sesquiterpene extract of the present invention, total sesquiterpene content is preferably better more than 60%.
In the Herba Saniculae lamelligerae sesquiterpene extract of the present invention, more preferably better more than 90%, 100% is best for total sesquiterpene content.
The medical usage of above-mentioned Herba Saniculae lamelligerae sesquiterpene extract is: the treatment influenza.The above-mentioned Herba Saniculae lamelligerae sesquiterpene extract that contains effective dose in the grippal medicine of said treatment.
Described pharmaceutical dosage form can be any existing pharmaceutical dosage forms such as powder pin, drop pill, tablet, slow releasing tablet, hard capsule, soft capsule, granule.
Compared with prior art, the invention has the beneficial effects as follows: prove that through pharmacodynamics and toxicology test this Herba Saniculae lamelligerae sesquiterpene extract can significantly suppress the effect of proliferation of influenza virus and antagonism mice influenza property pneumonia, and toxic and side effects is little.Not only effective ingredient (sesquiterpenoids) is clear and definite, and the content of total sesquiterpene is high more, and impurity is few more, and its effect is good more, and this can reduce dose, also can reduce toxic and side effects to a certain extent, more helps guaranteeing the safety and the effectiveness of medicine.Simultaneously, this Herba Saniculae lamelligerae sesquiterpene extract is different from the onset of chemicals single component, but the effect of " multicomponent, multipath, many target spots ", and toxic and side effects is little.
The present invention follows the trail of the effective site of Herba Saniculae lamelligerae, is that medicine makes an experiment with the Herba Saniculae lamelligerae sesquiterpene extract of different content, and the result has confirmed the grippal effect of Herba Saniculae lamelligerae sesquiterpene extract for treating.
The specific embodiment
Below in conjunction with the specific embodiment the present invention is made further detailed description.
But should this be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following embodiment.
Embodiment 1
Get Herba Saniculae lamelligerae medical material 100kg, add 70% alcohol reflux 2 times, each 1 hour, add the ethanol of 800kg70% the 1st time; Add the ethanol of 600kg70% the 2nd time, filter, merge extractive liquid,, extracting solution reclaims ethanol and is condensed into thick paste; Add an amount of anhydrous alcohol solution, mix thoroughly, add the water of dehydrated alcohol amount more than 10 times with macroporous adsorbent resin with weight; Stir, be added on and handled on the macroporous adsorptive resins, elder generation is eluted to colourless with 30% low-concentration ethanol; This 30% ethanol elution is discarded, and the ethanol elution of reuse 90% is collected this 90% ethanol elution to colourless; Reclaim ethanol and be condensed into the thick paste of relative density 1.25, vacuum drying promptly obtains containing the Herba Saniculae lamelligerae sesquiterpene extract of total sesquiterpene 30%.
Embodiment 2
Get Herba Saniculae lamelligerae medical material 100kg, add 90% alcohol reflux 2 times, each 1.5 hours, add the ethanol of 700kg90% the 1st time; Add the ethanol of 600kg90% the 2nd time, filter, merge extractive liquid,, extracting solution reclaims ethanol and is condensed into thick paste; Add an amount of anhydrous alcohol solution, mix thoroughly, add the water of dehydrated alcohol amount more than 10 times with macroporous adsorbent resin with weight; Stir, be added on and handled on the macroporous adsorptive resins, elder generation is eluted to colourless with 30% low-concentration ethanol; This 30% ethanol elution is discarded, and the ethanol elution of reuse 80% is collected this 80% ethanol elution to colourless; Reclaim ethanol and be condensed into the clear paste of relative density 1.10, spray drying promptly obtains containing the Herba Saniculae lamelligerae sesquiterpene extract of total sesquiterpene 60%.
Embodiment 3
Get Herba Saniculae lamelligerae medical material 100kg, add 80% alcohol reflux 2 times, each 2 hours, add the ethanol of 800kg80% the 1st time; Add the ethanol of 600kg80% the 2nd time, filter, merge extractive liquid,, extracting solution reclaims ethanol and is condensed into thick paste; Add an amount of anhydrous alcohol solution, mix thoroughly, add the water of dehydrated alcohol amount more than 10 times, stir with macroporous adsorbent resin with weight; Be added on and handled on the macroporous adsorptive resins, first low-concentration ethanol with 30% is eluted to colourless, and this 30% ethanol elution is discarded, and the ethanol elution of reuse 90% is to colourless; Collect this 90% ethanol elution, reclaim ethanol, vacuum drying promptly gets dry extract.This dry extract is added 5 times of water gagings make suspendible, with ethyl acetate extraction 4 times, the consumption of each ethyl acetate equates with sample volume, the combined ethyl acetate layer, and after the recovery ethyl acetate, vacuum drying promptly obtains containing the Herba Saniculae lamelligerae sesquiterpene extract of total sesquiterpene 90%.
Embodiment 4
Get Herba Saniculae lamelligerae medical material 100kg, add 90% alcohol reflux 3 times, each 1 hour, add the ethanol of 700kg90% the 1st time; 2nd, add the ethanol of 600kg90% respectively 3 times, filter, merge extractive liquid,, extracting solution reclaims ethanol and is condensed into thick paste; Add an amount of anhydrous alcohol solution, mix thoroughly, add the water of dehydrated alcohol amount more than 10 times with macroporous adsorbent resin with weight; Stir, be added on and handled on the macroporous adsorptive resins, elder generation is eluted to colourless with 30% low-concentration ethanol; This 30% ethanol elution is discarded, and the ethanol elution of reuse 75% is collected this 75% ethanol elution to colourless; Reclaim ethanol, vacuum drying promptly obtains containing the Herba Saniculae lamelligerae sesquiterpene extract of total sesquiterpene 60%.This Herba Saniculae lamelligerae sesquiterpene extract is added 5 times of water gagings make suspendible, with ethyl acetate extraction 4 times, the consumption of each ethyl acetate equates with sample volume; The combined ethyl acetate layer after the recovery ethyl acetate, adds 5 times of water gagings again and makes suspendible; Reuse ethyl acetate extraction 3 times, the consumption of each ethyl acetate equates the combined ethyl acetate layer with sample volume; Reclaim ethyl acetate, lyophilization promptly obtains containing the Herba Saniculae lamelligerae sesquiterpene extract of total sesquiterpene 100%.
Embodiment 5
Get Herba Saniculae lamelligerae medical material 20kg, be ground into fine powder, cross 80 mesh sieves, put into the carbon dioxide supercritical fluid extraction jar; Carbon dioxide flow is 12L/min, when temperature reaches 60 ℃, picks up counting when pressure is crossed 30Mpa, extracted 6 hours, from knockout drum tell the Herba Saniculae lamelligerae crude extract; This crude extract is added an amount of anhydrous alcohol solution, be added on the MCI Gel resin column of using water treatment, earlier with 30% ethanol elution; With this low-concentration ethanol eluent discard need not, the ethanol elution of reuse 80% is collected eluent; Reclaim ethanol, vacuum drying promptly obtains containing the Herba Saniculae lamelligerae sesquiterpene extract of total sesquiterpene 50%.
Embodiment 6
Get Herba Saniculae lamelligerae medical material 20kg, be ground into fine powder, cross 100 mesh sieves, put into the carbon dioxide supercritical fluid extraction jar; Carbon dioxide flow is 15L/min, when temperature reaches 60 ℃, picks up counting when pressure is crossed 30Mpa, extracted 8 hours, from knockout drum tell the Herba Saniculae lamelligerae crude extract; This crude extract is added an amount of anhydrous alcohol solution, be added on the MCI Gel resin column of using water treatment, earlier with 40% ethanol elution; With this low-concentration ethanol eluent discard need not, the ethanol elution of reuse 90% is collected eluent; Reclaim ethanol, vacuum drying promptly obtains containing the Herba Saniculae lamelligerae sesquiterpene extract of total sesquiterpene 65%.
Embodiment 7
Get described Herba Saniculae lamelligerae sesquiterpene extract 300g, dextrin 700g, mix homogeneously adopts existing hard capsule preparation technology, promptly makes the medicine of the hard capsule dosage form that contains Herba Saniculae lamelligerae sesquiterpene extract.
Embodiment 8
Get described Herba Saniculae lamelligerae sesquiterpene extract 3kg, vegetable oil 7kg, mix homogeneously is made capsule casing material with gelatin, adopts existing soft capsule preparation technology, promptly makes the medicine of the soft capsule dosage form that contains Herba Saniculae lamelligerae sesquiterpene extract.
Embodiment 9
Get described Herba Saniculae lamelligerae sesquiterpene extract 300g, Polyethylene Glycol
6000700g, mix homogeneously adopts existing drop pill preparation technology, promptly makes the medicine of the drops that contains Herba Saniculae lamelligerae sesquiterpene extract.
Embodiment 10
Get described Herba Saniculae lamelligerae sesquiterpene extract 300g, soluble starch 500g, sucrose 200g, mix homogeneously is granulated, and sieves, and drying promptly makes the medicine of the granule dosage form that contains Herba Saniculae lamelligerae sesquiterpene extract.Maybe, promptly make the medicine of the tablet that contains Herba Saniculae lamelligerae sesquiterpene extract with the further tabletting of the granule that makes.
Embodiment 11
Get described Herba Saniculae lamelligerae sesquiterpene extract 420g, hypromellose 60g, carboxymethyl starch sodium 8g; Microcrystalline Cellulose 10g, mix homogeneously adds magnesium stearate 1g again as lubricant; Tabletting promptly makes the medicine of the slow releasing tablet dosage form that contains Herba Saniculae lamelligerae sesquiterpene extract.
Embodiment 12
Get described Herba Saniculae lamelligerae sesquiterpene extract 300g, be dissolved in the 10000ml water for injection and (add a little ethanol and make dissolving), adopt the injectable powder freeze-drying preparation technology, promptly make the medicine of the injectable powder type that contains Herba Saniculae lamelligerae sesquiterpene extract.
Be effectiveness and the safety of investigating Herba Saniculae lamelligerae sesquiterpene extract of the present invention, the inventor is a trial drug with the described extract of above-mentioned part embodiment respectively, has carried out pharmacodynamics test and toxicology test and has investigated, and test method and result etc. distinguish as follows:
Pharmacodynamics test:
Test one, resisiting influenza virus test
Embryo Gallus domesticus: instar chicken embryo was available from Hunan Yahua Seed Industry Co., Ltd. on 10th.
Strain: the influenza A H1N1 influenza virus strain is provided by the disease prevention and control center, Hunan Province; Go down to posterity through 10 age in days chick embryo allantoic cavity inoculated and cultured, Microhemagglutination test dropping point virus, hemagglutinative titer is more than 1: 640;-70 ℃ of preservations are used with 1: 10 dilution back of physiological saline solution during experiment.
Medicine: Herba Saniculae lamelligerae sesquiterpene extract (what contain sesquiterpene 30% makes, contains being made by embodiment 3 of total sesquiterpene 90% by what embodiment 1 made, contains total sesquiterpene 60% by embodiment 2); Positive control drug: virazole injection (lot number 010523, Shanghai Hefeng Pharmaceutical Co., Ltd.).
Test method:
1, medicine is to the toxic detection of Embryo Gallus domesticus: with physiological saline solution medicine is carried out serial dilution.Herba Saniculae lamelligerae sesquiterpene extract and virazole injection are all got 4 concentration doses separately and are carried out the chick embryo allantoic cavity inoculation, 4 embryos of each concentration inoculation, and each embryo 0.2ml, 35 ℃ of cultivations are established the normal saline contrast, each embryo 0.2ml synchronously.Dead Embryo Gallus domesticus is not counted in the death toll of dealed with medicine went in the 24h.Observe continuously 4d, record Embryo Gallus domesticus survival confirms that medicine is to the maximal non-toxic of the Embryo Gallus domesticus (TC that limits the quantity of
0).
2, medicine is to the detection of influenza virus inhibited proliferation: instar chicken embryo was 63 on 10th, random packet: 3 of normal group; 4 of blank control group (adding normal saline 0.4ml); 4 of virus control; 4 of positive controls; 48 of drug group.With physiological saline solution Herba Saniculae lamelligerae sesquiterpene extract is diluted to 4 concentration respectively, is respectively: 200mg/ml, 100mg/ml, 50mg/ml and 25mg/ml.The viral liquid of dilution in 1: 10 is inoculated 10 age in days chick embryo allantoic cavities, and every embryo 0.2ml is behind 35 ℃ of cultivation 1h; The medicinal liquid 0.2ml of above-mentioned each concentration of every embryo injection cultivates 72h, 4 ℃ of refrigerator overnight for 35 ℃; Collect allantoic fluid, tire with Microhemagglutination test dropping point viral hemoagglutination.Simultaneously, the every embryo injection of positive controls 0.2ml virazole is cultivated synchronously, is measured.
The result: 1, medicine is to the toxic testing result of Embryo Gallus domesticus: Herba Saniculae lamelligerae sesquiterpene extract is 200mg/ml to the limes null of Embryo Gallus domesticus; The limes null of virazole injection is 100mg/ml; Physiological saline solution is to the Embryo Gallus domesticus toxic effects.
2, medicine is to the testing result of influenza virus inhibited proliferation: see table 1.Herba Saniculae lamelligerae sesquiterpene extract has the effect of obvious suppression proliferation of influenza virus, and is dose-effect relationship, and along with increasing of total sesquiterpene content wherein, its resisiting influenza virus effect strengthens.
Table 1 pair influenza virus inhibition of proliferation effect
Test two, to the in vivo test of influenza A H1N1 influenza virus effect
1 material
Medicine: Herba Saniculae lamelligerae sesquiterpene extract (what contain sesquiterpene 30% makes, contains being made by embodiment 3 of total sesquiterpene 90% by what embodiment 1 made, contains total sesquiterpene 60% by embodiment 2); Positive control drug: virazole injection (lot number 010523, Shanghai Hefeng Pharmaceutical Co., Ltd.).
Strain: influenza A H1N1 influenza virus Mus lung adapted strain (will provide) by the disease prevention and control center, Hunan Province.
Animal: NIH mice (will provide) by the Xiangya Medical College, Zhongnan Univ Experimental Animal Center.
The influence of 2 pairs of mice influenza property pneumonia
The NIH mice is divided into virus control group, normal control group, positive controls and the large and small dose groups of Herba Saniculae lamelligerae sesquiterpene extract, male and female half and half at random.Each drug group 5d before infecting begins gastric infusion, and matched group gives the co-content physiological saline solution and irritates stomach.Each group infects 15 LD of influenza A H1N1 influenza virus Mus lung adapted strain under the slight anesthesia of ether
50Infecting back 96h puts to death; Get the lung weighing after weighing; Calculate lung exponential quantity (being lung index=lung quality/body weight * 100) and lung index suppression ratio [(the average lung index of average lung index one experimental group of virus control the group)/average lung index of virus control group * 100%] one by one, and matched group is relatively organized a t check.
3 results: see table 2.
Table 2 Herba Saniculae lamelligerae sesquiterpene extract is to the influence of mice influenza A H1N1 pneumonia
The result shows: Herba Saniculae lamelligerae sesquiterpene extract has the effect of tangible antagonism mice influenza property pneumonia, and is dose-effect relationship, and along with increasing of total sesquiterpene content wherein, its effect strengthens.
Acute toxicity test:
In order to investigate the safety of Herba Saniculae lamelligerae sesquiterpene extract, the spy has carried out investigating of acute toxicity to it, and test method result is following:
Medicine: the Herba Saniculae lamelligerae sesquiterpene extract (containing total sesquiterpene 60%) that makes by embodiment 2.
Animal: ICR mice, one-level, Mus 8～9 weeks of age, body weight 18～22g.
Method: improvement bandit method (with reference to " herbal pharmacology research methodology " the 113rd page, People's Health Publisher, the 1st edition, Qi Chen chief editor).
Result: LD
50Be 16.89g/kg, 95% the credible 16.05～17.74g/kg that is limited to.
The result shows that medicine acute toxicity of the present invention is little, and degree of safety is big.
Result by above-mentioned pharmacodynamics and toxicology test can draw: Herba Saniculae lamelligerae sesquiterpene extract has treats grippal effect preferably, and LD
50Be 16.89g/kg, toxicity is very low.
Claims (6)
1. the Herba Saniculae lamelligerae sesquiterpene extract with anti-influenza A H 1 N 1 virus effect is characterized in that wherein total sesquiterpene content is more than 30%; And this Herba Saniculae lamelligerae sesquiterpene extract is through any one extracts from the Chinese medicine Herba Saniculae lamelligerae and makes in following two kinds of methods:
Method I comprises the steps:
(1) preparation Herba Saniculae lamelligerae crude extract: get the Herba Saniculae lamelligerae medical material, add 60%～95% ethanol and extract, filter, extracting solution, this extracting solution is concentrated, promptly get the Herba Saniculae lamelligerae crude extract;
(2) the Herba Saniculae lamelligerae crude extract that (1) step is made adds an amount of anhydrous alcohol solution, mixes thoroughly with the macroporous adsorbent resin with weight, adds the water of dehydrated alcohol amount more than 10 times; Stir, be added on handled on the low polar macroporous adsorbent resin column, earlier with 30% low-concentration ethanol eluting; With this low-concentration ethanol eluent discard need not, the ethanol elution of reuse 40%～95% is collected eluent; Reclaim ethanol, drying promptly gets Herba Saniculae lamelligerae sesquiterpene extract;
Method II comprises the steps:
(1) preparation Herba Saniculae lamelligerae crude extract: get the Herba Saniculae lamelligerae medical material, be ground into fine powder, put into the carbon dioxide supercritical fluid extraction jar, when temperature reaches 60 ℃, picks up counting when pressure is crossed 30Mpa, carbon dioxide flow is 12L/min, extracts 6 hours; Perhaps, carbon dioxide flow is 15L/min, extracted 8 hours, from knockout drum tell the Herba Saniculae lamelligerae crude extract;
(2) the Herba Saniculae lamelligerae crude extract that makes of (1) step is added an amount of anhydrous alcohol solution, be added on the MCI Gel resin column of using water treatment, earlier with 10%～40% ethanol elution; This low-concentration ethanol eluent is discarded need not; The ethanol elution of reuse 50%～95% is collected eluent, reclaims ethanol; Drying promptly gets Herba Saniculae lamelligerae sesquiterpene extract.
2. Herba Saniculae lamelligerae sesquiterpene extract according to claim 1 is characterized in that: total sesquiterpene content is more than 60% in the described Herba Saniculae lamelligerae sesquiterpene extract.
3. Herba Saniculae lamelligerae sesquiterpene extract according to claim 1 is characterized in that: total sesquiterpene content is more than 90% in the described Herba Saniculae lamelligerae sesquiterpene extract.
4. Herba Saniculae lamelligerae sesquiterpene extract according to claim 1 is characterized in that: make in the method for this extract, the Herba Saniculae lamelligerae sesquiterpene extract that (2) step makes is further purified processing with ethyl acetate.
5. the medical usage of each described Herba Saniculae lamelligerae sesquiterpene extract among the claim 1-3 is characterized in that: use it for the grippal medicine of preparation treatment H1N1.
6. Herba Saniculae lamelligerae sesquiterpene extract medical usage according to claim 5 is characterized in that: described pharmaceutical dosage form is any pharmaceutical dosage form in powder pin, drop pill, tablet, capsule, the granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102751242A CN101933961B (en) | 2010-09-08 | 2010-09-08 | Sanicula lamelligera hance sesquiterpene extract for treating influenza |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102751242A CN101933961B (en) | 2010-09-08 | 2010-09-08 | Sanicula lamelligera hance sesquiterpene extract for treating influenza |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101933961A CN101933961A (en) | 2011-01-05 |
| CN101933961B true CN101933961B (en) | 2012-05-30 |
Family
ID=43387682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102751242A Expired - Fee Related CN101933961B (en) | 2010-09-08 | 2010-09-08 | Sanicula lamelligera hance sesquiterpene extract for treating influenza |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101933961B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113730431B (en) * | 2021-08-31 | 2023-06-27 | 海南医学院 | Ficus pumila polysaccharide with antiviral effect and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD114256A1 (en) * | 1974-07-22 | 1975-07-20 | ||
| CN101152508A (en) * | 2007-09-24 | 2008-04-02 | 范玉堂 | Traditional Chinese medicine for treating children's pulmonitis |
-
2010
- 2010-09-08 CN CN2010102751242A patent/CN101933961B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD114256A1 (en) * | 1974-07-22 | 1975-07-20 | ||
| CN101152508A (en) * | 2007-09-24 | 2008-04-02 | 范玉堂 | Traditional Chinese medicine for treating children's pulmonitis |
Non-Patent Citations (2)
| Title |
|---|
| Ali Karagoz,et al.Antiviral activity of Sanicula europaea L. extracts on multiplication of human parainfluenza virus type 2.《PHYTOTHERAPY RESEARCH》.1999,第13卷(第5期),第436-438页. * |
| 蔡锐,等.肺经草抗甲型H1N1流感有效部位的研究.《亚太传统医药》.2010,第6卷(第5期),第30-31页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101933961A (en) | 2011-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yu et al. | Subchronic toxicity studies of Radix Astragali extract in rats and dogs | |
| CN102961439B (en) | Total flavone extract of Hyssopus officinalis, preparation method thereof and application thereof | |
| CN103768308A (en) | Medicament composition for treating upper respiratory infections and preparation method thereof | |
| CN101129455B (en) | Sophora extractive and method of preparing the same and application of the same | |
| CN1872105A (en) | Application of holly and extractive in preparing medication for anti virus | |
| CN101850032B (en) | Anti-tumor traditional Chinese medicine composition and preparation method and application thereof | |
| CN101773532B (en) | Carpesium abrotanoides total terpene lactones extract | |
| CN101933961B (en) | Sanicula lamelligera hance sesquiterpene extract for treating influenza | |
| CN106420919A (en) | Preparation method and application of Nepeta bracteatatotal flavonoids | |
| CN106721225A (en) | A kind of honeysuckle composition pig feed additive | |
| CN104435567A (en) | Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout | |
| CN103463395A (en) | Pharmaceutical formulation for treating respiratory disease of chickens | |
| CN103330781A (en) | Traditional Chinese medicine composite with anti-tumor effect and preparation method of injection of same | |
| CN103880913B (en) | A kind of compound and application thereof with hepatoprotective effect | |
| CN102813713A (en) | Rhizoma dryopteris crassirhizomae and fructus crataegi composition, preparation method and application of composition | |
| CN102697800B (en) | Herba stellariae mediae polysaccharide composition and the application in preparation antiviral drugs thereof | |
| CN101721450B (en) | Application of oriental cocklebur root chloroform extract used for treating peritonitis | |
| CN104815007A (en) | Medicinal composition for preventing and treating infectious bronchitis of chicken as well as preparation method and application thereof | |
| CN101380356B (en) | Tibetan medicine Duyiwei total flavone extract and extraction method and use thereof | |
| CN103316103A (en) | Coccidian-expelling and dysentery-stopping mixture for livestock and preparation method thereof | |
| CN104208168B (en) | A kind of for compound traditional Chinese medicine composite treating poultry respiratory infection and preparation method thereof | |
| CN102078529B (en) | Chinese medicinal preparation for treating common cold in children | |
| CN102579731B (en) | Chinese herbal preparation for treating chronic respiratory diseases | |
| CN102526509A (en) | Medicine for treating hepatomegaly | |
| CN102429946B (en) | Chinese medicinal composition for preparing anti-influenza virus medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20110105 Assignee: Sanjin Group Hunan Sanjin Pharmaceutical Co., Ltd. Assignor: Zhou Xiaojiang Contract record no.: 2013430000044 Denomination of invention: Sanicula lamelligera hance sesquiterpene extract for treating influenza Granted publication date: 20120530 License type: Exclusive License Record date: 20130428 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhou Xiaojiang Document name: Notification to Pay the Fees |
|
| ASS | Succession or assignment of patent right |
Owner name: SANJIN GROUP HUNAN SANJIN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHOU XIAOJIANG Effective date: 20140811 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 410007 CHANGSHA, HUNAN PROVINCE TO: 415001 CHANGDE, HUNAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140811 Address after: 415001 Hunan city of Changde province hill town economic and Technological Development Zone Chongde Road No. 320 Hill neighborhood Patentee after: Sanjin Group Hunan Sanjin Pharmaceutical Co., Ltd. Address before: 410007 Hunan province Changsha labor Road No. 61 building 202 Yahua champs Huadu 15 Patentee before: Zhou Xiaojiang |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120530 Termination date: 20160908 |